Straits Times Index
3,176.93 -10.73 (-0.34%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,235.20 -150.67 (-0.92%) FTSE 100
7,877.05 0.00 (0.00%) Bitcoin USD
64,751.14 +3,546.41 (+5.79%) CMC Crypto 200
1,332.92 +20.30 (+1.55%)
MorphoSys AG (0NDV.L)
| Previous close | 22.32 |
| Open | 22.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 22.31 - 22.39 |
| 52-week range | 11.84 - 32.37 |
| Volume | |
| Avg. volume | 31,216 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
- Reuters SG
Deals of the day-Mergers and acquisitions
** Novo Nordisk notched a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for $16.5 billion. ** Brazilian fashion companies Arezzo & Co and Grupo Soma said they had agreed to a merger to form an entity with yearly revenues of 12 billion reais ($2.42 billion), which will be 54% controlled by Arezzo. ** Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said.
